

ENANTIOSPECIFIC SYNTHESIS OF AMINO ACIDS: PREPARATION OF (*R*)- AND (*S*)- $\alpha$ -  
METHYLASPARTIC ACID FROM (*S*)-TRYPTOPHAN

Chat-On Chan,<sup>a</sup> David Crich,<sup>\*, a, b</sup> and Swaminathan Natarajan<sup>b</sup>

<sup>a</sup> Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, UK, and

<sup>b</sup> Department of Chemistry (M/C 111), University of Illinois at Chicago, Chicago, Illinois 60680-4348, USA


**Summary:** The enantiospecific synthesis of both antipodes of  $\alpha$ -methylaspartic acid from (*S*)-tryptophan is described with the key steps being alkylation of the hexahydropyrroloindole **4**, oxidative degradation of indoles and, for the preparation of the (*R*)-isomer, Barton reductive decarboxylation.

The asymmetric synthesis of natural and unnatural non-proteinogenic amino acids is an area of considerable interest at the present time.<sup>1</sup> The  $\alpha$ -disubstituted amino acids, in particular, are of interest owing to the increased lipophilicity<sup>2</sup> and increased resistance to exo- and endo-peptidases and to chemical hydrolysis<sup>3</sup> that they confer on peptides into which they are included.  $\alpha$ -Disubstituted amino acids are also known to stabilise helical domains in peptides<sup>4</sup> and have found extensive use as enzyme inhibitors.<sup>5</sup> In this laboratory we have developed an enantiospecific synthesis of  $\alpha$ -substituted tryptophan derivatives from (*S*)-tryptophan. The underlying principle of our method is the alkylation, with clean retention of configuration, of the derived hexahydropyrrolo[2,3-b]indole **3**.<sup>6, 7</sup> We report here on the extension of this tryptophan based methodology to the preparation of  $\alpha$ -substituted aspartic acid derivatives as exemplified by the enantiospecific synthesis of both (*R*)- and (*S*)- $\alpha$ -methylaspartic acids, of interest owing to their ability to competitively inhibit aspartate amino transferase.<sup>8</sup>

As previously described, the (*S*)-tryptophan derivative **1** was converted in high yield to its cyclic tautomer (**2**).<sup>6, 9</sup> by dissolution in 85% phosphoric acid at room temperature. Sulfonylation with benzenesulfonyl


\* Address correspondence to this author in Chicago

chloride in pyridine then gave the sulfonamide **4**, as a single diastereoisomer, in 69% yield. The benzenesulfonamide (**4**) is preferred over the *p*-toluenesulfonamide (**3**), employed in our initial work, owing to its high degree of crystallinity which enables preparation of 50g batches without recourse to chromatography.<sup>10, 11</sup> Deprotonation of **4** with lithium diisopropylamide in tetrahydrofuran under an inert atmosphere at -78 °C followed by treatment of the so-formed yellow enolate with methyl iodide gave the crystalline 2-methyl derivative (**5**) in 95% yield as a single diastereoisomer. Similarly, quenching of the enolate with methyl bromoacetate gave **6**, again as a single, crystalline, diastereoisomer in essentially quantitative yield. The assignment of relative configuration in **5** and **6** is greatly facilitated by the typical<sup>6</sup> <sup>1</sup>H-nmr chemical shift of δ3.05 for a C-2 CO<sub>2</sub>Me on the *endo*-face of the diazabicyclooctane system, where it is shielded by the aromatic ring current. Stirring of **5** and **6** in trifluoroacetic acid at room temperature for 1h gave the corresponding tryptophan derivatives (**7**) and (**8**) quantitatively.




Oxidative cleavage of **7** was achieved, essentially as described for tryptophan containing dipeptides by Ranganathan,<sup>12</sup> by heating to reflux in aqueous acetonitrile with a 20 molar excess of sodium metaperiodate and 2 mole% of ruthenium trichloride trihydrate. After silica gel chromatography the (*S*)-aspartic acid derivative **9** was isolated in 64% yield. Application of the same procedure to **8** gave **10**, chiral simply by virtue of its differentially protected side chains, in 68% yield. The byproduct from this oxidative cleavage process was the sulfonamide **12**. We view this oxidation as proceeding via the kynurenine derivatives **13** with subsequent Baeyer-Villiger type cleavage of the aryl ketone, and hydrolysis of the so-formed aryl ester and formamide groups. We also wish to stress that the oxidation was operative on the *N*-sulfonylindoles, in contrast to the oxidations described by Ranganathan<sup>12</sup> in which the indoles were unprotected.

The acid **10** was decarboxylated, according to the Barton *O*-acyl thiohydroxamate protocol,<sup>13</sup> by stirring in dichloromethane with triethylamine and reagent **14** followed by immediate *in situ* white light photolysis in the presence *t*-butyl mercaptan to give the (*R*)-aspartic acid derivative **11** in 83% yield.



Finally, deprotection of **9** and **11** was achieved by heating to reflux for 1h in 6M hydrochloric acid giving the enantiomeric (*S*)- and (*R*)- $\alpha$ -methylaspartic acids (**15**)  $\{[\alpha]_D = +33.5^0, (c = 1.54, \text{MeOH})\}$ , and (**16**)  $\{[\alpha]_D = -35.13^0, (c = 1.27, \text{MeOH})\}$  respectively in the form of their hygroscopic hydrochloride salts in excellent yield. The enantiomeric purity of **15** and **16** follows from the extreme propensity of **4** to undergo alkylation on its *exo*-face. For the purpose of comparison with literature data **15** was converted to the corresponding zwitterion (**17**) by ion exchange chromatography. The measured optical rotation of **17**  $\{[\alpha]_D = +52.2, c = 0.45, \text{H}_2\text{O}\}$  corresponds well with literature values for samples obtained by asymmetric synthesis  $\{[\alpha]_D = +55.3^0 (c = 0.67, \text{H}_2\text{O})\}$  for **17**<sup>14</sup> and by partial synthesis from resolved material  $\{[\alpha]_D = -52.9^0 (c = 0.68, \text{H}_2\text{O})\}$  for the enantiomer.<sup>15</sup> The minor variations observed in optical rotations between samples are, almost certainly, a function of the difficulty in removing all traces of water from these somewhat hygroscopic substances.



The methodology described in this communication makes possible the enantiospecific synthesis of many  $\alpha$ -substituted aspartic acid derivatives from commercially available **4** and thence, by manipulation of the side chain

acid, of a wide range of  $\alpha$ -disubstituted amino acids.

**Acknowledgements:** We thank the SERC and ICI Pharmaceuticals Ltd for support to C-O. C. through the CASE Award Scheme and the University of Illinois at Chicago for support.

**References:**

- For excellent surveys of synthetic efforts in this area see: Williams, R.M. *Synthesis of Optically Active  $\alpha$ -Amino Acids*; Pergamon Press, 1989; Wagner, I.; Musso, H. *Angew. Chem. Int. Ed. Engl.* 1983, 22, 816; Fiant, S. in *Chemistry and Biochemistry of Amino Acids*; Ed. Barrett, G.C., Chapman and Hall, London, 1985, pp 55; Izumi, Y.; Chibata, I.; Itoh, I. *Angew. Chem. Int. Ed. Engl.* 1978, 17, 176; Valentine, D.; Scott, J.W. *Synthesis*. 1978, 329; Drauz, K.; Kleeman, A.; Martens, J. *Angew. Chem. Int. Ed. Engl.* 1982, 21, 584; Schöllkopf, U. *Topic Curr. Chem.* 1983, 109, 65; Martens, J. *Topic Curr. Chem.* 1984, 125, 167; Kochetkov, K.A.; Belikov, V.M. *Russ. Chem. Rev.* 1987, 56, 1045; Seebach, D.; Imwinkelreid, R.; Weber, T. in *Modern Synthetic Methods*; Ed. Scheffold, R., Springer Verlag, Berlin, 1986, 4, 128; Coppola, G.M.; Schuster, H.F. *Asymmetric Synthesis: Construction of Chiral Molecules using Amino Acids*; Wiley, New York, 1987.
- See for example: Christensen, H.N.; Handlogten, M.E.; Vadgama, J.V.; de la Cuesta, E.; Ballesteros, P.; Trigo, G.C.; Avendaño, C. *J. Med. Chem.* 1983, 26, 1374; Deeks, T.; Crooks, T.P.A.; Waigh, R.D. *J. Med. Chem.* 1983, 26, 762.
- See for example: Turk, J.; Panse, G.T.; Marshall, G.R. *J. Org. Chem.* 1975, 40, 953; Khosla, M.C.; Stackowiak, K.; Smeby, R.R.; Bumpus, F.M.; Piriou, F.; Lintner, K.; Femandijan, S. *Proc. Natl. Acad. Sci., USA.* 1981, 78, 757 and references therein.
- For lead references see: Toniolo, C.; Bonora, G.M.; Bavoso, A.; Benedetti, E.; Di Blasio, B.; Pavone, V.; Pedrone, C. *Biopolymers*, 1983, 22, 205; Bosch, R.; Jung, G.; Schmidt, H.; Winters, W. *Biopolymers*, 1985, 24, 979; Smith, G.D.; Pletnev, V.Z.; Duax, W.L.; Balasubramanian, H. E.; Bosshard, H.E.; Czerwinski, E.; Kendrick, N.C.E.; Mathews, S.F.; Marshall, G.R. *J. Am. Chem. Soc.* 1981, 103, 1493.
- For excellent reviews of this field see: Jung, M.J. in *Chemistry and Biochemistry of Amino Acids*; Ed. Barrett, G.C., Chapman and Hall, London, 1985, pp 227; Shire, W.; Skinner, C.G. in *Metabolic Inhibitors*; Eds. Hochster, R.M.; Quastel, J.H. Academic Press, New York, 1963, 1, 1.
- Crich, D.; Davies, J.W. *J. Chem. Soc., Chem. Commun.* 1989, 1418; Bourne, G.T.; Crich, D.; Davies, J.W.; Horwell, D.C. *J. Chem. Soc., Perkin Trans. 1.* 1991, 1693.
- For a review on the chemistry of cyclic tautomers of tryptophan see: Hino, T.; Nakagawa, M. in *The Alkaloids*; Ed. Brossi, A., Academic Press, 1988, 34, 1.
- Kiick, D. M.; Cook, P. F. *Biochemistry*, 1983, 22, 375, and references therein.
- Taniguchi, M.; Hino, T. *Tetrahedron*, 1981, 37, 1487.
- All new compounds gave satisfactory spectroscopic and microanalytical data.
- Chan, C-O.; Cooksey, C.J.; Crich, D. *J. Chem. Soc., Perkin Trans.1*, 1992, 0000; The sulfonamide 4 is commercially available from Aldrich Chemical Company.
- Ranganathan, S.; Ranganathan, D.; Bhattacharyya, D. *J. Chem. Soc., Chem. Commun.* 1987, 1085.
- Barton, D.H.R.; Crich, D.; Motherwell, W.B. *Tetrahedron*. 1985, 41, 3901; Crich, D.; Quintero, L. *Chem. Rev.* 1989, 89, 1413.
- Aebi, J.D.; Seebach, D. *Helv. Chim. Acta*, 1985, 68, 1507.
- Terashima, S.; Achiwa, K.; Yamada, S. *Chem. Pharm. Bull.*, 1966, 14, 1138.